Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Asks For Road Map To Broader NRT Indications

This article was originally published in The Tan Sheet

Executive Summary

While the agency appears to favor moving to a broad harm reduction framework for indications for NRTs, including lifting limits on recommended duration of use, there remains “a lot of devil in the details” of expanding indications.

Advertisement

Related Content

Smoking Cessation Label Changes Could Lay Groundwork For Indications
FDA Allows Smoking Cessation Labels Without Use Limit
Experts Advocate Easing NDA Clinical Trial Requirements For Nicotine Replacement Therapies
Experts Advocate Easing NRT NDA Clinical Trial Requirements
FDA Delves Into Broader Smoking Cessation Approach
NRT Petition Calls On FDA To Greatly Expand Indications, Availability
U.K. NRT Harm Reduction Indication Could Be Model For U.S.
GSK Asks FDA To Mull Expansion Of NRT Indications
Make Smoking Cessation OTCs As Available As Cigarettes – Petition

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS106158

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel